Antibody-drug conjugate (ADC) therapy is a proven, revolutionary approach designed to target specific tumor cells with high precision while minimizing toxicity to healthy cells.Good ADC therapy development decisions start with dependable research which translates into accurate, reliable testing protocols and results.Adopting a robust, sensitive, and specific biomarker assay facilitates the correct identification of patients most likely to respond to ADC therapy. This personalized approach allows for selection of predicted responders while avoiding harmful side effects in those unlikely to respond, thus shortening the drug development for this class of compounds.
ISCT 2024
Vancouver Convention Centre 1055 Canada Pl, Vancouver, British Columbia, CanadaJoin Discovery Life Sciences at ISCT 2024 Stop by our booth #453 or schedule a meeting with our CGT team. May 28- 31, 2024 | Vancouver, Canada Schedule a Meeting at ISCT